- US-listed companies
- Atara Biotherapeutics, Inc.
- Income statement
Atara Biotherapeutics, Inc. (ATRA) Income statement
Market cap
$27.72M
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | - | - | - | - | - | - | 9 | 129 |
| Revenue growth (%) | - | - | - | - | - | - | - | - | - | - | |
| Research & development | - | - | 57 | 81 | 167 | 216 | 245 | 282 | 273 | 225 | 151 |
| Operating margin (%) | - | - | - | - | - | - | - | - | - | ||
| Operating expenses | 28 | 58 | 81 | 122 | 237 | 296 | 309 | 361 | 344 | 285 | 212 |
| Operating income | -28 | -58 | -81 | -122 | -237 | -296 | -309 | -340 | -281 | -276 | -83 |
| Income before tax | -28 | -57 | -79 | -120 | -231 | -291 | -307 | -340 | -228 | -276 | -85 |
| Pretax margin (%) | - | - | - | - | - | - | - | - | - | -3,220.7 | -66.2 |
| Provision for income taxes | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Effective tax rate (%) | |||||||||||
| Net income | -28 | -57 | -79 | -119 | -231 | -291 | -307 | -340 | -228 | -276 | -85 |
| Net income margin (%) | - | - | - | - | - | - | - | - | - | ||
| Earnings per share | - | - | - | - | - | - | - | - | -2.24 | -2.61 | -11.41 |
| Diluted EPS | - | - | - | - | - | - | - | - | -2.24 | -2.61 | -11.41 |